Effect of 7-Day Therapy with Different Doses of the Proton Pump Inhibitor Lansoprazole on the Intragastric pH in Healthy Human Subjects

References

• Fellinus E, Berglindh T, Sachs G. Substituted benzimidazoles inhibit gastric acid secretion by blocking (H+/K+) ATPase. Nature 1991;290:159–61.
   Google Scholar
• Cederberg C, Andersson T, Skanberg I. Omeprazole: pharmacokinetics and metabolism in man. Scand J Gastroenterol 1989;166:33–40.
   Google Scholar
• Simon A. The H+/K+ ATPase sites that react selectively with the benzimidazole class of anti-ulcerogen drugs. Gastroenterology 1993;104:A192.
   Google Scholar
• Barradell LB, Faulds D, McTavish D. Lansoprazole. A review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy in acid-related disorders. Drugs 1992; 44:225–50.
   Google Scholar
• Spencer CM, Faulds D. Lansoprazole. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy in acid-related disorders. Drugs 1994;48: 404–30.
   Google Scholar
• Langtry HD, Wilde MI. Lansoprazole. An update of its pharmacological properties and clinical efficacy in the management of acid-related disorders. Drugs 1997;54:473–500.
   Google Scholar
• Brunner G, Hell M, Hengels KJ, Hennig U, Fuchs W. Influence of lansoprazole on intragastric 24-hour pH, meal stimulated gastric acid secretion, and concentrations of gastrointestinal hormones and enzymes in serum and gastric juice in healthy volunteers. Digestion 1995;56: 137–44.
   Google Scholar
• Toleman KG. Gastric pH levels after 15 mg and 30 mg lansoprazole and 20 mg omeprazole. Gastroenterology 1994; 106:A197.
   Google Scholar
• Dammann HG, von-zur-Muhlen A, Balks HJ, Damaschke A, Steinhoff J, Hennig U, et al. The effects of lansoprazole, 30 or 60 mg daily, on intragastric pH and on endocrine function in healthy volunteers. Aliment Pharmacol Ther 1993;7: 191–6.
   Google Scholar
• Hongo M, Ohara S, Hirasawa Y, Abe S, Asaki S, Toyota T. Effect of lansoprazole on intragastric pH: comparison between morning and evening dosing. Dig Dis Sci 1992;37:882–90.
   PubMedGoogle Scholar
• Berlin I, Molinier P, Duchier A, Cournot A, Durrel J, Dellatolas F, et al. Dose ranging study of lansoprazole, a new proton pump inhibitor, in patients with high gastric acid secretion. Eur J Clin Pharmacol 1992;43:117–9.
   PubMed Web of Science ®Google Scholar
• Bell NJV, Hunt RH. Time to maximum effect of lansoprazole on gastric pH in normal male volunteers. Aliment Pharmacol Ther 1996;10:897–904.
   PubMed Web of Science ®Google Scholar
• Dammann HG, Fuchs W, Richter G, Burkhardt F, Wolf N, Walter TA. Lansoprazole versus omeprazole: influence on mealstimulated gastric acid secretion. Aliment Pharmacol Ther 1997;11:359–64.
   PubMedGoogle Scholar
• Blum RA, Vermeire GD, Shi H. Gastric pH levels with lansoprazole 15 mg and 30 mg qd, omeprazole 20 mg qd, and ranitidine 150 mg qid. Gastroenterology 1997;112:A73.
   Google Scholar
• Blum RA, Hunt RH, Kidd S. Pharmacodynamics of various doses of lansoprazole. Am J Gastroenterol 1997;89:A75.
   Google Scholar
• Bruley des Varannes S, Levy P, Lartigue S, Dellatolas F, Lemaire M, Galmiche JP. Comparison of lansoprazole with omeprazole on 24-hour intragastric pH, acid secretion and serum gastrin in healthy volunteers. Aliment Pharmacol Ther 1994; 8:309–14.
   PubMed Web of Science ®Google Scholar
• Brummer RJM, Geerling BJ, Stockbrügger RW. Initial and chronic gastric acid inhibition by lansoprazole and omeprazole in relation to meal administration. Dig Dis Sci 1997;42:2132–7.
   Google Scholar
• Timmer W, Ripke H, Kleist P, Ehrlich A, Wieckhorst G, Lucker PW, et al. Effect of four lansoprazole dose levels and one dosage regimen of omeprazole on 24-hour intragastric pH in healthy subjects. Meth Find Exp Clin Pharmacol 1995;17:89–95.
   PubMedGoogle Scholar
• Harder H, Teyssen S, Stephan F, Pfützer R, Kiel G, Singer MV. Comparison of the effect of a 7-day therapy with a low to high dose of the proton pump inhibitor lansoprazole on the intragastric pH in healthy human subjects. Gastroenterology 1997;112:A258.
   Google Scholar
• Bell GD, Powell K, Weil J, Harrison G, Brookes S, Prosser S. 13-C urea breath test for helicobacter pylori infection. Gut 1991;32:551–2.
   PubMedGoogle Scholar
• Fimmel C, Etienne A, Cilluffo T, von Ritter C, Gasser T, Rey JP, et al. Long-term ambulatory gastric pH-monitoring: validation of a new method and effect of H-2 antagonists. Gastroenterology 1985;88: 1842–51.
   Google Scholar
• Walsh JH. Radioimmunoassay of gastrin. In: Rothfeld B, editor. Nuclear medicine in vitro. Philadelphia: Lippincott; 1974. p. 231–48.
   Google Scholar
• Hotz J, Kleinert R, Grymbowski T, Hennig U, Schwarz JA. Wirksamkeit und Verträglichkeit von Lansoprazol im Vergleich zu Famotidin in der Akuttherapie des Duodenalulcus. Aliment Pharmacol Ther 1992;6:87–95.
   Google Scholar
• Bardhan KD, Ahlberg J, Hislop E, Lindholmer C, Long RG, Morgan AG, et al. Rapid healing of gastric ulcers with lansoprazole. Aliment Pharmacol Ther 1994;8:215–20.
   PubMed Web of Science ®Google Scholar
• Dorsch E. Lansoprazole heals moderate to severe reflux oesophagitis. Am J Gastroenterol 1991;86:1294.
   Google Scholar
• Benhaim MC, Evreux M, Saducci J, Petite JP, Lemaire M. Lansoprazole and ranitidine in treatment of reflux oesophagitis: double-blind comparative study. Gastroenterology 1990;98:A20.
   Google Scholar
• Feljou JF. Efficacy and safety of 24-week treatment with lansoprazole (30 mg/day) following healing of peptic lesions resistant to H-2 blockers. Gastroenterology 1993;104:2.
   Google Scholar
• Brunner G, Arnold R, Hennig U, Fuchs W. An open trial of long-term therapy with lansoprazole in patients with peptic ulceration resistant to extended high-dose ranitidine treatment. Aliment Pharmacol Ther 1993;1:51–5.
   Google Scholar
• Gough AL, Long RG, Cooper BT, Fosters CS, Garrett AD, Langworthy CH. Lansoprazole versus ranitidine in the maintenance treatment of reflux oesophagitis. Aliment Pharmacol Ther 1996;10:529–39.
   PubMed Web of Science ®Google Scholar
• Penson J, Puttemans M, Fourie E. Safety of lansoprazole in maintenance therapy for reflux esophagitis. Gut 1995;37:A 163.
   Google Scholar
• Robinson M, Lanza F, Avner D, Haber M. Effective maintenance treatment of reflux oesophagitis with low-dose lansoprazole. Ann Intern Med 1996;124:859–67.
   PubMed Web of Science ®Google Scholar
• Burget DW, Chiverton SG, Hunt RH. Is there an optimal degree of acid suppression for healing duodenal ulcers? A model of relationship and acid suppression. Gastroenterology 1990;99: 345–51.
   Google Scholar
• Howden CW, Hunt RH. Relationship between gastric secretion and infection. Gut 1987;28:96–107.
   PubMed Web of Science ®Google Scholar
• Teyssen S, Chari ST, Joos A, Singer MV. Effect of a 28-day therapy with famotidine on blood levels of alcohol and gastrin and intragastric pH in healthy human subjects. Scand J Gastroenterol 1994;29:398–405.
   PubMed Web of Science ®Google Scholar
• Teyssen S, Chari ST, Scheid J, Singer MV. Effect of repeated boluses of intravenous omeprazole and primed infusions of ranitidine on 24-hour intragastric pH in healthy human subjects. Dig Dis Sci 1995;40:247–55.
   Google Scholar
• DeRojas FD, Berenguer J, Rodrigo L, Aran-Suau R, Da Silveira JC, Clerch L, et al. Omeprazole and ranitidine in long term treatment of duodenal ulcer. Dig Dis Sci 1998;43:1964–9.
   Google Scholar
• Annibale B, Franceschi M, Fusillo M, Beni M, Cesana B, Delle Fave G. Omeprazole in patients with mild or moderate reflux esophagitis induces lower relapse rates than ranitidine during maintenance treatment. Hepatogastroenterology 1998;45:742–51.
   Google Scholar
• Venables TL, Newland RD, Patel AC, Hole J, Wilcock C, Turbitt ML. Omeprazole 10 milligrams once daily, omeprazole 20 milligrams once daily or ranitidine 150 milligrams twice daily, evaluated as initial therapy for the relief of symptoms of gastro-oesophageal reflux disease in general practice. Scand J Gastroenterol 1997;32:965–73.
   PubMed Web of Science ®Google Scholar
• Delchier JC, Benamouzig R, Stanescu L, Ropert A, Vallot T, Wirquin V, et al. Twenty-four-hour intragastric acidity and plasma gastrin during 3-month treatment with omeprazole in healthy subjects. Aliment Pharmacol Ther 1997;11:747–53.
   PubMedGoogle Scholar
• Levy MJ, Seelig CB, Robinson NJ, Ranney JE. Comparison of omeprazole and ranitidine for stress ulcer prophylaxis. Dig Dis Sci 1997;42:1255–9.
   PubMed Web of Science ®Google Scholar
• Castell DO, Richter JE, Robinson M, Sontag SJ, Haber MM. Efficacy and safety of lansoprazole in the treatment of erosive reflux esophagitis. The Am J Gastroenterol 1996;91:9.
   Google Scholar
• McCullough AJ, Graham DY, Knuff TE, Lanza FL, Levenson HL, Lyon DT, et al. Suppression of nocturnal acid secretion accelerates gastric ulcer healing. Gastroenterology 1989;97: 860–6.
   PubMed Web of Science ®Google Scholar
• Sanders SW, Tolmann HG, Gresk PA, Jennings DE, Hoyos PA, Page JG. The effect of lansoprazole, a new H+,K+ ATPase inhibitor on gastric pH and serum gastrin. Aliment Pharmacol Ther 1992;6:359–72.
   PubMedGoogle Scholar
• Dammann HG. The effects of lansoprazole, 30 or 60 mg daily on intragastric pH and on endocrine function in healthy volunteers. Aliment Pharmacol Ther 1993;7:191–6.
   PubMedGoogle Scholar
• Petite JP, Slama JL, Licht H, Lemerez M, Coste T, Andrieu J, et al. Comparison du lansoprazole (30 mg) et de l’oméprazole (20 mg) dans le traitement de l’ulcère duodénal. Gastroenterol Clin Biol 1989;17:334–0.
   Google Scholar
• Aaronson R. Lansoprazole heals duodenal ulcer. Am J Gastroenterol 1991;86:1307.
   Google Scholar
• Bertaccini G, Coruzzi G. Regulation of receptors on parietal cells on acid secretion. Scand J Gastroenterol 1988;23 Suppl 146:22–33.
   Google Scholar
• McGuigan J. Inhibition of hydrogen-potassium-stimulated adenosine triphosphatase: effects on acid secretion, plasma gastrin and the gastric mucosa. Gastroenterology 1989;97: 1045–8.
   PubMedGoogle Scholar